Overview
Mankind Pharma Limited is a leading Indian pharmaceutical company engaged in manufacturing and marketing a broad spectrum of pharmaceutical products and healthcare solutions. The company operates in both acute and chronic therapeutic areas, with a notable presence in cardiovascular, anti-diabetic, and neuro/CNS segments.
In Q3 FY26, Mankind Pharma reported a revenue increase of 11.5% YoY, driven by strong domestic pharmaceutical performance. Adjusted EBITDA margins improved to 25.9%, showcasing robust operational efficiency.
The expansion into specialty and super specialty segments via BSV acquisition has marked significant growth, with BSV now contributing substantially to Mankind's revenue and offering a high entry barrier to competitors.
Mankind Pharma's consumer healthcare segment showed resilience with a 5.2% growth in Q3 FY26, bolstered by high-performing brands like Gas-O-Fast and Manforce, and increasing contributions from e-commerce and modern trade channels.
Strategic transformations in workforce and operational strategies have bolstered Mankind's foundation, positioning it for sustainable long-term growth and enhanced market position across its pharma and consumer healthcare segments.
- Sector
Pharmaceuticals & Biotechnology
- Industry
Pharmaceuticals
- Market Cap
82,460 Cr
- Volatility
Low Risk
- P/E Ratio
46.2
- Industry P/E
30.9
- PEG Ratio
1.3
- P/B Ratio
5.4
- 52W High
2,726.75
- 52W Low
1,909.90
Financial Ratios
Sales CAGR
- 1Y
- 18.98%
- 3Y
- 8.26%
- 5Y
- 14.65%
- 10Y
- —
Profit CAGR
- 1Y
- 3.57%
- 3Y
- 10.69%
- 5Y
- 14.48%
- 10Y
- —
ROE
- TTM
- 11.45%
- 3Y
- 15.78%
- 5Y
- 17.38%
- 10Y
- —
ROCE
- TTM
- 12.34%
- 3Y
- 17.21%
- 5Y
- 20.05%
- 10Y
- —
Technicals
Oscillators
Neutral
Bearish
4
Neutral
7
Bullish
3
Overall
Bearish
Bearish
36
Neutral
7
Bullish
3
Moving Averages
Bearish
Bearish
32
Neutral
0
Bullish
0
Peers
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2276.80 | 1,04,091 Cr | 20.96 | 5.30 | 0.53 | 22.03 | 21.92 | 13.94 | ||
1218.00 | 1,01,628 Cr | 18.23 | 2.82 | 0.66 | 16.03 | 18.66 | 10.16 | ||
1193.40 | 96,401 Cr | 21.21 | 2.93 | 1.34 | 16.53 | 21.05 | 11.32 | ||
864.25 | 86,964 Cr | 17.61 | 3.44 | 1.27 | 19.44 | 19.08 | 10.52 | ||
1990.00 | 82,460 Cr | 46.23 | 5.39 | 0.00 | 11.45 | 12.34 | 6.26 | ||
1335.95 | 77,592 Cr | 22.25 | 2.21 | 0.00 | 9.77 | 12.69 | 6.63 | ||
5271.35 | 62,857 Cr | 26.58 | 4.71 | 0.86 | 17.69 | 18.13 | 11.95 | ||
| Median: 7 Co. | — | 1335.95 | 86,964 Cr | 21.21 | 3.44 | 0.66 | 16.53 | 18.66 | 10.52 |
Price Chart Comparison
Documents
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI
